title: Ptosis during hematologic malignancy in children.
abstract: Neurological symptoms such as ptosis may develop due to either chemotherapeutic agents or involvement of the central nervous system (CNS) during hematologic malignancy. It is difficult to make this distinction according to clinical symptoms and magnetic resonance imaging findings. If the neurologic symptoms are increased, it is a warning of CNS involvement. Herein are described the clinical and neuroimaging features of three patients with hematologic malignancy who presented with ptosis.
authors.affiliation: Department of Pediatric Neurology, Osmangazi University Medicine Faculty, Eskisehir, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Ekici
authors.forename: Ayten
authors.initials: A
authors.lastname: Yakut
authors.forename: Özcan
authors.initials: Ö
authors.lastname: Bör
authors.forename: Sevgi
authors.initials: S
authors.lastname: Yimenicioğlu
authors.forename: Kürşat Bora
authors.initials: KB
authors.lastname: Çarman
authors.forename: Suzan
authors.initials: S
authors.lastname: Saylısoy
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001763:Blepharoptosis / Q000139:chemically induced*; D002675:Child, Preschool; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male
chemical_list: D000970:Antineoplastic Agents
keywords: central nervous system; chemotherapeutic agent; hematologic malignancy; neurotoxicity; ptosis